Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
182.54
+6.18 (3.50%)
Aug 20, 2026, 2:19 PM EDT - Market open
Repligen Employees
Repligen had 2,000 employees as of December 31, 2025. The number of employees increased by 222 or 12.49% compared to the previous year.
Employees
2,000
Change (1Y)
222
Growth (1Y)
12.49%
Revenue / Employee
$392,551
Profits / Employee
$20,770
Market Cap
10.30B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,000 | 222 | 12.49% |
| Dec 31, 2024 | 1,778 | -5 | -0.28% |
| Dec 31, 2023 | 1,783 | -242 | -11.95% |
| Dec 31, 2022 | 2,025 | 173 | 9.34% |
| Dec 31, 2021 | 1,852 | 724 | 64.18% |
| Dec 31, 2020 | 1,128 | 367 | 48.23% |
| Dec 31, 2019 | 761 | 213 | 38.87% |
| Dec 31, 2018 | 548 | 72 | 15.13% |
| Dec 31, 2017 | 476 | 240 | 101.69% |
| Dec 31, 2016 | 236 | 68 | 40.48% |
| Dec 31, 2015 | 168 | 32 | 23.53% |
| Dec 31, 2014 | 136 | 20 | 17.24% |
| Dec 31, 2013 | 116 | -4 | -3.33% |
| Dec 31, 2012 | 120 | -17 | -12.41% |
| Dec 31, 2011 | 137 | 69 | 101.47% |
| May 6, 2010 | 68 | -1 | -1.45% |
| May 31, 2009 | 69 | 13 | 23.21% |
| May 27, 2008 | 56 | 11 | 24.44% |
| Jun 30, 2007 | 45 | 2 | 4.65% |
| Jun 6, 2006 | 43 | 6 | 16.22% |
| Jun 7, 2005 | 37 | -3 | -7.50% |
| Jun 7, 2004 | 40 | -4 | -9.09% |
| May 15, 2003 | 44 | 5 | 12.82% |
| May 15, 2002 | 39 | -1 | -2.50% |
| May 15, 2001 | 40 | 13 | 48.15% |
| May 15, 2000 | 27 | 3 | 12.50% |
| May 15, 1999 | 24 | 0 | - |
| May 29, 1998 | 24 | 4 | 20.00% |
| May 15, 1997 | 20 | 5 | 33.33% |
| Jun 14, 1996 | 15 | -89 | -85.58% |
| Mar 31, 1995 | 104 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Baxter International | 37,500 |
| Solventum | 20,584 |
| Align Technology | 20,290 |
| Teleflex | 15,500 |
| The Cooper Companies | 15,000 |
| AptarGroup | 14,000 |
| Avantor | 13,500 |
| Bausch + Lomb | 13,000 |
RGEN News
- 1 day ago - Stifel sees Moderna data as positive for Repligen, Maravai - TheFly
- 1 day ago - Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data - TheFly
- 22 days ago - Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures - TipRanks
- 22 days ago - Repligen price target raised to $175 from $165 at JPMorgan - TheFly
- 23 days ago - Repligen rises 15.4% - TheFly
- 23 days ago - Repligen rises 16.2% - TheFly
- 23 days ago - Repligen Earnings Call Transcript: Q2 2026 - Transcripts
- 23 days ago - Repligen Earnings release: Q2 2026 - Filings